https://doi.org/10.55788/e107858a
Ms Zi-Rou Jiang (National Yang Ming Chiao Tung University, Taiwan) and colleagues designed a study in mice to determine the role of glymphatics in cortical spreading depolarisation [1]. The cortical spreading depolarisation events were induced with potassium chloride or an optogenetic method before and after cerebrospinal fluid tracer injection. Glymphatic dynamics were assessed using macroscopic imaging, while glymphatic clearance was assessed by monitoring the tracer transitioning into the deep cervical lymph node.
“The cerebrospinal fluid tracer signal was always larger on the contralateral side than on the ipsilateral side,” said Ms Jiang. “We also saw that at the moment of cortical spreading depolarisation induction, the cerebrospinal fluid tracer signal showed a rapid and abundant influx in the ipsilateral side.” The cerebrospinal fluid tracer signal was found to be significantly increased in the ipsilateral side at all timepoints assessed following cortical spreading depolarisation (at 30, 60, 90, and 120 minutes). Finally, drainage of the cerebrospinal fluid was also assessed with the tracer, showing that fluorescence decreased in the ipsilateral compared with contralateral deep cervical lymph node after spreading depolarisation induction, “potentially altering glymphatic function,” added Ms Jiang.
“In conclusion, our study indicated that optogenetically-induced spreading depolarisation evokes rapid influx but delayed clearance of the glymphatic flow,” said Ms Jiang. “We clearly saw a difference between the control group and the cortical spreading depolarisation group, potentially indicating that a cortical spreading depolarisation event can alter glymphatic function, not only in the efflux but also in the influx.”
- Jiang Z, et al. Optogenetically-induced spreading depolarization evokes rapid influx but delayed clearance of the glymphatic flow. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome Next Article
The locus coeruleus is involved in processing pain in migraine »
« Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome Next Article
The locus coeruleus is involved in processing pain in migraine »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
October 2, 2020
Beta-blocker eye drops may alleviate migraine pain
January 6, 2025
Nitroglycerin-induced migraine targetable by different agents
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
